1. |
Majumder J, Minko T. Recent developments on therapeutic and diagnostic approaches for COVID-19. AAPS J, 2021, 23(1): 14.
|
2. |
Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis, 2008, 198(7): 962-970.
|
3. |
Martin Loeches I, Corral AS, Diaz E, et al. Community-acquired respiratory coinfection in critically ill patients with pandemic 2009 influenza A (H1N1) virus. Chest, 2011, 139(3): 555-562.
|
4. |
Rice TW, Lewis R, Timothy MU, et al. Critical illness from 2009 pandemic influenza A virus and bacterial coinfection in the United States. Crit Care Med, 2012, 40(5): 1487-1498.
|
5. |
Mutair, A, Ambani Z, Narrative review of Middle East respiratory syndrome coronavirus (MERS-CoV) infection: updates and implications for practice. J Int Med Res, 2020, 48(1): 30-58.
|
6. |
Nassar MS, Bakhrebah MA, Meo SA, et al. Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection: epidemiology, pathogenesis and clinical characteristics. Eur Rev Med Pharmacol Sci, 2018, 22(15): 4956-4961.
|
7. |
Musuuza J, Watson L, Parmasad V, et al. Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: a systematic review and meta-analysis. PLoS One, 2021, 16(5): e0251170.
|
8. |
Westblade LF, Simon MS, Satlin M J. Bacterial coinfections in coronavirus disease 2019. Trends Microbiol, 2021, 29(10): 930-941.
|
9. |
Karami Z, Bram T, Anton SM. Few bacterial co-infections but frequent empiric antibiotic use in the early phase of hospitalized patients with COVID-19: results from a multicentre retrospective cohort study in The Netherlands. Infect Dis (Lond), 2021, 53(2): 102-110.
|
10. |
Vaughn, VM, Gandhi TN, Petty LA, et al. Empiric antibacterial therapy and community-onset bacterial coinfection in patients hospitalized with coronavirus disease 2019 (COVID-19): a multi-hospital cohort study. Clin Infect Dis, 2021, 72(10): e533-e541.
|
11. |
Elabbadi A, Matthieu T, Grigoris T, et al. Bacterial coinfection in critically ill COVID-19 patients with severe pneumonia. Infection, 2021, 49(3): 559-562.
|
12. |
Kolenda C, Ranc AG, Boisset S, et al. Assessment of respiratory bacterial coinfections among severe acute respiratory syndrome coronavirus 2-positive patients hospitalized in intensive care units using conventional culture and BioFire, FilmArray Pneumonia Panel plus assay. Open Forum Infect Dis, 2020, 7(11): ofaa484.
|
13. |
Contou, D, Claudinon A, Pajot O, et al. Bacterial and viral co-infections in patients with severe SARS-CoV-2 pneumonia admitted to a French ICU. Ann Intensive Care, 2020, 10(1): 119-125.
|
14. |
胡明, 李绪言, 邱海波, 等. 新型冠状病毒肺炎患者继发细菌感染防治的体会与建议. 中华重症医学电子杂志, 2020, 6(2): 230-232.
|
15. |
Huang L, Wang Y, Wang L, et al. Coronavirus disease 2019 (COVID-19) pneumonia in a hemodialysis patient: a case report. Medicine (Baltimore), 2020, 99(27): e20956.
|
16. |
Luo Y, Xie YL, Zhang WJ, et al. Combination of lymphocyte number and function in evaluating host immunity. Aging (Albany NY), 2019, 11(24): 12685-12707.
|
17. |
Naveen KV, Saravanakumar K, Sathiyaseelan A, et al. Human fungal infection, immune response, and clinical challenge - a perspective during COVID-19 pandemic. Appl Biochem Biotechnol, 2022, 10(7): 151-178.
|
18. |
赖展翔, 范颖敏, 欧静怡, 等. 新型冠状病毒肺炎合并细菌及真菌感染的诊疗特点. 实用医学杂志, 2021, 37(1): 16-19.
|
19. |
Singulani JL, Danielle LS, Caroline ML, et al. The impact of COVID-19 on antimicrobial prescription and drug resistance in fungi and bacteria. Braz J Microbiol, 2022, 53(4): 1925-1935.
|
20. |
Seitz T, Holbik J, Grieb A, et al. The role of bacterial and fungal superinfection in critical COVID-19. Viruses, 2022, 14(12): 2785.
|
21. |
王蓉, 谢伶俐, 杜鹏, 等. 新型冠状病毒肺炎96例临床分析. 中国呼吸与危重监护杂志, 2020, 19(2): 144-147.
|
22. |
Wang L, Amin AK, Priya K, et al. An observational cohort study of bacterial co-infection and implications for empirical antibiotic therapy in patients presenting with COVID-19 to hospitals in North West London. J Antimicrob Chemother, 2021, 76(3): 796-803.
|
23. |
Nasir N, Rehman FU, Omair SF. Risk factors for bacterial infections in patients with moderate to severe COVID-19: a case-control study. J Med Virol, 2021, 93(7): 4564-4569.
|
24. |
Patton MJ, Orihuela CJ, Harrod KS, et al. COVID-19 bacteremic co-infection is a major risk factor for mortality, ICU admission, and mechanical ventilation. Crit Care, 2023, 27(1): 34-45.
|
25. |
Schons MJ, Caliebe A, Spinner CD, et al. All-cause mortality and disease progression in SARS-CoV-2-infected patients with or without antibiotic therapy: an analysis of the LEOSS cohort. Infection, 2022, 50(2): 423-436.
|
26. |
Abdela SG, Liesenborghs L, Tadese F, et al. Antibiotic overuse for COVID-19: are we adding insult to injury? Am J Trop Med Hyg, 2021, 105(6): 1519-1520.
|
27. |
Langford BJ, So M, Raybardhan S, et al. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. Clin Microbiol Infect, 2021, 27(4): 520-531.
|
28. |
Gao CA, Pickens CI, Nebreda LM, et al. Clinical features of COVID-19 and differentiation from other causes of CAP. Semin Respir Crit Care Med, 2023, 44(1): 8-20.
|
29. |
黄秋芬, 曾惠清, 王洺辉 等. 新型冠状病毒肺炎严重程度相关生物学预测因子的研究进展. 中国呼吸与危重监护杂志, 2022, 21(1): 71-75.
|
30. |
Heer RS, Mandal AJ, Kho J, et al. Elevated procalcitonin concentrations in severe Covid-19 may not reflect bacterial co-infection. Ann Clin Biochem, 2021, 58(5): 520-527.
|
31. |
Peng XH, Cruz CSD, Sharma L. Coronaviruses, lysosomes, and secondary bacterial infections: coronaviruses outsmart the host. DNA Cell Biol, 2023, 42(4): 189-193.
|
32. |
Pettit NN, Nguyen TC, Alison KL, et al. Reducing the use of empiric antibiotic therapy in COVID-19 on hospital admission. BMC Infect Dis, 2021, 21(1): 516-529.
|
33. |
Puzniak L, Bauer KA, Kalvin C, et al. Effect of inadequate empiric antibacterial therapy on hospital outcomes in SARS-CoV-2-positive and -negative US patients with a positive bacterial culture: a multicenter evaluation from march to november 2020. Open Forum Infect Dis, 2021, 8(6): 232-248.
|
34. |
Sieswerda E, Mark GJ, Bonten MJ, et al. Recommendations for Antibacterial Therapy in Adults with COVID-19 - An Evidence Based Guideline. Clin Microbiol Infect, 2021, 27(1): 61-66.
|
35. |
Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med, 2021, 47(11): 1181-1247.
|
36. |
World Health Organization. Coronavirus disease (COVID-19) technical guidance.https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance2021.
|
37. |
Calderon M, Grace G, Sarah W, et al. , Bacterial co-infection and antibiotic stewardship in patients with COVID-19: a systematic review and meta-analysis. BMC Infect Dis, 2023, 23(1): 14-29.
|